aiqbench analysis
This research addresses a critical bottleneck in computational drug discovery by demonstrating that preserving fine-grained chemical and geometric information during data representation is more impactful than simply increasing the complexity of downstream AI models. The study validates that loss of fidelity at the input stage fundamentally limits prediction accuracy, establishing representation integrity as a foundational design principle for next-generation affinity predictors.
Chemical and geometric representation fidelity improves drug--target affinity prediction
arXiv:2609.13230v1 Announce Type: cross Abstract: Predicting drug--target binding affinity (DTA) requires models to distinguish subtle chemical and structural determinants underlying molecular recognition. Although recent approaches increasingly incorporate richer drug and protein information, such information may be compressed, homogenized or discretized during representation construction, causing affinity-relevant distinctions to be lost before interaction modelling. We hypothesized that this representation-stage information loss constitutes an upstream bottleneck that cannot be reliably overcome by increasingly complex interaction predictors. To test this hypothesis, we developed ReGeoDTA, a representation-preserving framework that maintains affinity-relevant chemical heterogeneity in molecular representations and continuous geometric relationships in protein structures. Across three benchmark datasets, ReGeoDTA consistently improved affinity prediction, and the proposed representation-preserving strategies retained their benefits across diverse DTA architectures. Controlled representation degradation progressively reduced predictive performance, whereas increasing downstream predictor complexity failed to recover information lost during representation construction. These findings identify representation fidelity as an upstream design principle for accurate and generalizable drug--target affinity prediction, with potential implications for computational compound prioritization.
Abstract:Predicting drug--target binding affinity (DTA) requires models to distinguish subtle chemical and structural determinants underlying molecular recognition. Although recent approaches increasingly incorporate richer drug and protein information, such information may be compressed, homogenized or discretized during representation construction, causing affinity-relevant distinctions to be lost before interaction modelling. We hypothesized that this representation-stage information loss constitutes an upstream bottleneck that cannot be reliably overcome by increasingly complex interaction predictors. To test this hypothesis, we developed ReGeoDTA, a representation-preserving framework that maintains affinity-relevant chemical heterogeneity in molecular representations and continuous geometric relationships in protein structures. Across three benchmark datasets, ReGeoDTA consistently improved affinity prediction, and the proposed representation-preserving strategies retained their benefits across diverse DTA architectures. Controlled representation degradation progressively reduced predictive performance, whereas increasing downstream predictor complexity failed to recover information lost during representation construction. These findings identify representation fidelity as an upstream design principle for accurate and generalizable drug--target affinity prediction, with potential implications for computational compound prioritization.
Biomolecules (q-bio.BM); Artificial Intelligence (cs.AI); Machine Learning (cs.LG); Machine Learning (stat.ML)
arXiv:2609.13230 [q-bio.BM]
(or arXiv:2609.13230v1 [q-bio.BM] for this version)
https://doi.org/10.48550/arXiv.2609.13230 Focus to learn more arXiv-issued DOI via DataCite
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Full text under the publisher's open licence · 258 words
Related coverage
How to build a cancer vaccine, and whether they will work this time
LessWrong · Jun 8, 2026
Language-Informed Flow Matching for Trend-Guided Structure-Based 3D Molecular Generation
arXiv · Sep 1, 2026

Quantum Chemicals & Quantum Life Science July 8-15
Inside Quantum Technology · Jul 8, 2026

NVIDIA and Japan Bring Full-Stack AI and Robotics to Every Industry
NVIDIA · Jul 15, 2026